ASH 2019 – CLL

Mantle-cell lymphoma is a relatively aggressive type of non-Hodgkin lymphoma. Results from a study of patients who elected to interrupt treatment with ibrutinib plus venetoclax are presented. Read More ›

Targeted drug treatments for patients with relapsed and refractory chronic lymphocytic leukemia (CLL) are given indefinitely: either until disease progression or until side effects are no longer manageable. A key question is whether oncologists can use results of minimal residual disease (MRD) testing to determine if patients can take a break from treatment with targeted drugs. Read More ›

Updated analysis of ASCEND trial showed that acalabrutinib, a highly selective Bruton tyrosine kinase inhibitor, improves progression-free survival compared with other treatments for patients with relapsed and refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Read More ›

Diffuse large B-cell lymphoma is an aggressive type of non-Hodgkin lymphoma that is particularly difficult to treat if the patient becomes refractory to or relapses after initial treatment. Chances of survival are especially poor for people who are not eligible for stem-cell transplant. Read More ›

A study evaluating the safety and efficacy of a new 3-drug combination is underway in patients with relapsed and refractory chronic lymphocytic leukemia (CLL). Read More ›

Results from a study of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to see if treatment with ibrutinib plus venetoclax could be stopped for those who have a good response. Read More ›

Primary analysis results of a phase 1b/2 trial showed obinutuzumab + polatuzumab vedotin + lenalidomide was associated with high complete response rates and a favorable safety profile in heavily pretreated and refractory patients with follicular lymphoma. Read More ›

Extended follow-up of the E1912 trial showed a significant advantage for patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib + rituximab compared with those treated with fludarabine, cyclophosphamide, and rituximab (FCR). Read More ›

Zanubrutinib is an investigational, next-generation Bruton tyrosine kinase inhibitor. It has been tested in previously untreated patients with del(17p) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who are enrolled in the SEQUOIA trial. Read More ›

An updated analysis of combined or pooled data from studies of ibrutinib. For the first time, a comparison of outcomes with ibrutinib versus patients’ prior treatment regimens for mantle-cell lymphoma is shared. Read More ›

Page 1 of 4

Conference Correspondent Coverage is Brought to You by the Publishers of:
CONQUER: the patient voice

Learn more about our family of publications.

View Our Publications